Table 2.
Main Characteristics of the Four Immunoassays Evaluated.
| Anti-SARS-CoV-2 QuantiVac ELISA (IgG) | Architect AdviseDx SARS-CoV-2 IgG II | Elecsys Anti-SARS-CoV-2 S | LIAISON SARS-CoV-2 TrimericS IgG | |
|---|---|---|---|---|
| Manufacturer | EUROIMMUN Medizinische Labordiagnostika Ag | Abbott Diagnostics Division | Roche Diagnostics | DiaSorin Inc. |
| Clinical using Labeling | HC & FDA EUA | HC & FDA EUA | HC & FDA EUA | HC & FDA EUA |
| Detection of IgG antibodies | Quantitative | Quantitative | Quantitative | Quantitative |
| Measuring interval | 3.2–384.0 | 3.1–3550.0 | 0.40–250.0 | 4.81–2,080.0 |
| Units | BAU/mL | BAU/mL | BAU/mL | BAU/mL |
| Cut off (positive) | ≥35.2Borderline Range (≥25.6 to < 35.2) |
≥7.1 | ≥0.80 | ≥33.8 |